Ultra-Rapid Nanopore Sequencing Reshapes Precision Medicine Across Transplantation, Infectious Disease, and Oncology
核心洞察
Nanopore sequencing delivers long reads, real-time data streaming, and portability, reducing turnaround times to as little as four hours compared with 24–72 hours for short-read platforms.
The technology enables high-resolution HLA (搜索) typing for transplantation, rapid pathogen and antimicrobial resistance (搜索) detection, pharmacogenomics, and oncology applications including liquid biopsy and intraoperative diagnostics.
Recent chemistry and base-calling advances have raised median read accuracy to Q32 (99.93%), while adaptive sampling allows PCR-free, on-device target enrichment in 4–24 hours.
Nanopore sequencing has emerged as a transformative force in precision medicine, offering unprecedented speed, ultra-long reads, and portability at comparatively low cost. According to a review published in Frontiers in Immunology, these attributes are fundamentally reshaping clinical diagnostics and personalized medicine, with pivotal applications in time-sensitive areas such as HLA (搜索) matching in transplantation, infectious disease management, pharmacogenomics, and oncology.
Technological Advances Driving Clinical Adoption
Oxford Nanopore Technologies (搜索) (ONT) sequencing is a third-generation technology in which single-stranded DNA or RNA molecules pass through a protein nanopore, inducing current changes that are directly translated into sequence information. Unlike short-read platforms, which typically produce reads of 150–300 base pairs and require turnaround times of 24–36 hours for variant calling, ONT sequencing can reduce total assay time to only a few hours, with a minimum turnaround of roughly four hours. The platform also supports ultra-long reads reaching into the megabase scale, native capture of nucleic acid modifications such as 5-(hydroxy)methyl-cytosine and N6-methyl-adenosine, and throughput of up to 1.9 terabases per run.
Early ONT protocols demonstrated higher error rates, particularly in homopolymer-rich and high-GC regions. However, continued advances in flow-cell design, assay chemistry, and deep-learning base-calling algorithms—including transformer models and bi-directional recurrent neural networks—have now achieved median read accuracies as high as Q32 (99.93%). Duplex sequencing, which reads both template and complement DNA strands, further improves precision. As of 2025, ONT has begun promoting a routine, scalable 24-hour sample-to-variant human whole-genome sequencing workflow for clinical research.
Adaptive Sampling and Accessibility
Adaptive sampling enables selective enrichment or depletion of specific genomic regions in real time without PCR-based pre-amplification, allowing enrichment or depletion of up to 10% of the human genome. In pioneer clinical cancer settings, adaptive sampling has been reported to detect genomic driver alterations, methylation classification, and DNA copy-number information in real time in as little as 15–30 minutes, with more comprehensive molecular profiling within 6–24 hours, even at low coverage (10x). The technique offers a PCR-free enrichment approach with a total turnaround time of only 4 to 24 hours.
The portability of ONT devices—MinION, GridION, and PromethION—enables bedside and field-based diagnostics, reducing reliance on centralized sequencing facilities. In 2025, ONT and Cepheid announced a strategic collaboration to integrate GeneXpert cartridge-based sample preparation with ONT sequencing, aiming for a scalable, automated, "hours not days" infectious disease workflow.
Transplantation and HLA Typing
The highly polymorphic human leukocyte antigen (HLA (搜索)) region harbors the genes typed to identify well-matched hematopoietic stem cell donors. In a proof-of-principle study of 33 clinical samples, Matern et al. compared ONT versus Sanger sequencing across 70 HLA class I allele groups and demonstrated 100% typing concordance, with complete concordance in an independent validation cohort of 67 samples. Multicenter proof-of-principle studies in Europe and the US reported ONT sequencing for HLA typing as a "laboratory in a suitcase" assay requiring only 40–50 ng genomic DNA input, with a total turnaround of 8 hours and an assay cost of approximately $80 per sample.
For solid organ transplantation, where deceased-donor organs must be screened and HLA (搜索)-typed within 4 to 12 hours, targeted ONT sequencing is already being applied. Both the Genome Canada Transplant Consortium and Fiona Stanley Hospital in Perth, Australia, have demonstrated the feasibility of high-throughput epitope-based matching using ONT sequencing.
Infectious Disease and Antimicrobial Resistance
In 2019, total annual deaths from infections were estimated at 13.7 million worldwide, of which 1.27 million were directly caused by antimicrobial resistance (搜索) (AMR), with AMR playing a contributing role in an additional 3.6 million deaths. ONT sequencing has advanced the discovery of AMR genes in pathogens including P. aeruginosa, N. gonorrhoeae, Campylobacter, K. pneumoniae, and M. tuberculosis (搜索), achieving reproducibility accuracies of 98 to 100% in AMR gene detection. Several proof-of-concept prospective clinical studies have reported high accuracy in pathogen and AMR gene detection superior to culture-based approaches in as little as four hours of turnaround time.
The technology's regulatory standing has strengthened: the 2024 WHO approval of the ONT AmPORE TB assay, a rapid whole-genome-sequencing-based alternative to culture-based drug susceptibility testing, signals growing regulatory confidence in nanopore sequencing for high-stakes infectious disease decisions.
Oncology, Liquid Biopsy, and Intraoperative Diagnostics
Nanopore sequencing facilitates non-invasive tumor monitoring through circulating cell-free DNA analysis, enabling early cancer detection, treatment-response monitoring, and identification of minimal residual disease and emerging resistance mutations. The Personalized OncoGenomics program at BC Cancer reported that ONT-based sequencing significantly improves the validation, resolution, and classification of germline structural variants in advanced and metastatic cancer patients.
In intraoperative diagnostics, a proof-of-principle study by Wadden et al. achieved 250x sequencing coverage and called a known H3F3A histone variant from a pediatric tumor sample within intraoperative time frames of less than 35 minutes, at an estimated cost of approximately $388 per sample. The ONT-based MethyLYZR approach achieved 100% concordance in molecular classification of 10 nervous system malignancy biopsies with a total turnaround time of 40 minutes.
Remaining Challenges
Despite these advances, ONT sequencing still faces technical limitations, including lower per-read accuracy relative to some platforms, reduced sequencing yield, and challenges with homopolymer regions longer than 10 bases. In a comparison of the newest R10.4.1 flow cell against Ion Torrent sequencing, R10.4.1 demonstrated a median Phred quality of 19.7 and raw read accuracy of 97.6–97.9%, still lower than the 99.2–99.3% achieved by Ion Torrent. Standardization of analysis workflows, robust version control, and the current lack of reference data across species and base-modification subtypes remain among the biggest barriers to realizing the full clinical potential of nanopore sequencing data.
Looking ahead, the authors envision a distributed genomic medicine model in which portable sequencing platforms enable testing in regional hospitals and transplant centers, while cloud-based pipelines and centralized expert interpretation support same-day reporting of clinically actionable results. As sequencing turnaround times continue to decrease, the principal bottlenecks are likely to shift from data generation toward interpretation, clinical reporting, and electronic health record integration.